252 related articles for article (PubMed ID: 31227381)
1. Azithromycin plus β-lactam versus levofloxacin plus β-lactam for severe community-acquired pneumonia: A retrospective nationwide database analysis.
Suzuki J; Sasabuchi Y; Hatakeyama S; Matsui H; Sasahara T; Morisawa Y; Yamada T; Yasunaga H
J Infect Chemother; 2019 Dec; 25(12):1012-1018. PubMed ID: 31227381
[TBL] [Abstract][Full Text] [Related]
2. Azithromycin combination therapy for community-acquired pneumonia: propensity score analysis.
Ito A; Ishida T; Tachibana H; Tokumasu H; Yamazaki A; Washio Y
Sci Rep; 2019 Dec; 9(1):18406. PubMed ID: 31804572
[TBL] [Abstract][Full Text] [Related]
3. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
[TBL] [Abstract][Full Text] [Related]
5. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
[TBL] [Abstract][Full Text] [Related]
6. Diagnosis and management of community-acquired pneumonia in adults.
Watkins RR; Lemonovich TL
Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
[TBL] [Abstract][Full Text] [Related]
7. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
Mortensen EM; Restrepo MI; Anzueto A; Pugh J
Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Kyriazopoulou E; Sinapidis D; Halvatzis S; Velissaris D; Alexiou N; Kosmas V; Adami ME; Kyprianou M; Kyprianou A; Stefos A; Lada M; Koutoukas P; Pavlaki M; Kyriakoudi A; Makina A; Gogos C; Niederman MS; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2020 Jan; 55(1):105836. PubMed ID: 31704213
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of β-Lactam Monotherapy vs Macrolide Combination Therapy for Children Hospitalized With Pneumonia.
Williams DJ; Edwards KM; Self WH; Zhu Y; Arnold SR; McCullers JA; Ampofo K; Pavia AT; Anderson EJ; Hicks LA; Bramley AM; Jain S; Grijalva CG
JAMA Pediatr; 2017 Dec; 171(12):1184-1191. PubMed ID: 29084336
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
[TBL] [Abstract][Full Text] [Related]
11. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.
Garin N; Genné D; Carballo S; Chuard C; Eich G; Hugli O; Lamy O; Nendaz M; Petignat PA; Perneger T; Rutschmann O; Seravalli L; Harbarth S; Perrier A
JAMA Intern Med; 2014 Dec; 174(12):1894-901. PubMed ID: 25286173
[TBL] [Abstract][Full Text] [Related]
12. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
[TBL] [Abstract][Full Text] [Related]
13. Narrow-spectrum ß-lactam monotherapy in hospital treatment of community-acquired pneumonia: a register-based cohort study.
Rhedin S; Galanis I; Granath F; Ternhag A; Hedlund J; Spindler C; Naucler P
Clin Microbiol Infect; 2017 Apr; 23(4):247-252. PubMed ID: 28017793
[TBL] [Abstract][Full Text] [Related]
14. Respiratory fluoroquinolone monotherapy vs. β-lactam plus macrolide combination therapy for hospitalized adults with community-acquired pneumonia: A systematic review and meta-analysis of randomized controlled trials.
Choi SH; Cesar A; Snow TAC; Saleem N; Arulkumaran N; Singer M
Int J Antimicrob Agents; 2023 Sep; 62(3):106905. PubMed ID: 37385561
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia.
Zervos M; Mandell LA; Vrooman PS; Andrews CP; McIvor A; Abdulla RH; de Caprariis PJ; Knirsch CA; Amsden GW; Niederman MS; Lode H
Treat Respir Med; 2004; 3(5):329-36. PubMed ID: 15606222
[TBL] [Abstract][Full Text] [Related]
17. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
[TBL] [Abstract][Full Text] [Related]
18. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort.
Ito A; Ishida T; Tokumasu H; Washio Y; Yamazaki A; Ito Y; Tachibana H
BMC Pulm Med; 2017 May; 17(1):78. PubMed ID: 28464807
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic treatment strategies for community-acquired pneumonia in adults.
Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
